solute carrier organic anion transporter family member 4C1Genealiases: OATP-H · OATP-M1 · OATP4C1 · OATPX · PRO2176 · SLC21A20
Q-omics provides the consensus-scored SLCO4C1 profile across patient tissues and cancer cell-line models. SLCO4C1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLCO4C1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SLCO4C1 RNA expression shows 17,713 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where SLCO4C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLCO4C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLCO4C1 survival associations across molecular data types. SLCO4C1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLCO4C1 RNA expression–survival associations across cancer types. High SLCO4C1 expression shows unfavorable associations in UCEC, DLBC and LIHC, but favorable associations in KIRC, PAAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLCO4C1 RNA expression.
This table summarizes SLCO4C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLCO4C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLCO4C1 shows lower tumor expression in KICH, COAD, LUAD and LUSC and higher tumor expression in THCA and BLCA. The KICH box plot shows higher SLCO4C1 RNA expression in normal versus tumor tissue (log2 FC = −3.995, t-test p < 0.001).
This table shows molecular features associated with SLCO4C1 in patient tissues and cancer cell lines. In patient samples, SLCO4C1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SLCO4C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
